

Pediatric Latent TB Infection Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](#).

Medicines	WHO Guidelines (LTBI '18)	EMLc submitted	EMLc (2019)	WHO PQ EOI (2019)	WHO PQ submitted	WHO PQ listed	Global Fund ERP EOI (Aug 2019)	Global Fund approved	GDF Catalog	Status
Isoniazid 50mg dispersible tablet	Yes	No	No	No	Yes	No	No	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion
Isoniazid 50mg tablet scored	Yes	Yes	Yes	No	No	No	No	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion
Isoniazid 50mg/5mL oral liquid	Yes	Yes	Yes	No	No	No	No	Ineligible for inclusion	No	Ineligible for inclusion
Isoniazid 100mg dispersible tablet	Yes	Yes	Yes	Yes	Yes	No	Yes	No	Yes	Ineligible for inclusion
Isoniazid 100mg tablet	Yes	Yes	Yes	No	Yes	Yes	No	Ineligible for inclusion	Yes	Ineligible for inclusion
Isoniazid 300mg tablet/capsule	Yes	Yes	Yes	Yes	N/A	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Ineligible for inclusion
Rifampicin 20mg/mL oral liquid	Yes	Yes	Yes	No	No	No	No	Ineligible for inclusion	No	Ineligible for inclusion
Rifampicin/Isoniazid 75/50 dispersible tablet	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

Status
● Yes
● No
● Ineligible for inclusion
● N/A

LTBI: Latent TB Infection
 EML: Essential Medicines List
 EOI: Expression of Interest
 ERP: Expert Review Panel
 SRA: Stringent Regulatory Authority
 WHO PQ: World Health Organization Prequalification of Medicines Programme

Pediatric Latent TB Infection Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](#).

Medicines	WHO Guidelines (LTBI '18)	EMLc submitted	EMLc (2019)	WHO PQ EOI (2019)	WHO PQ submitted	WHO PQ listed	Global Fund ERP EOI (Aug 2019)	Global Fund ERP approved	GDF Catalog	Status
Rifapentine 150mg dispersible tablet	Yes	No	No	Yes	No	No	No	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion
Rifapentine 300mg scored, dispersible	Yes	No	No	Yes	No	No	No	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion
Rifapentine/Isoniazid 150mg/150mg dispersible tablet	Yes	No	No	Yes	No	No	No	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion
Rifapentine/Isoniazid 300mg/300mg dispersible tablet	Yes	No	No	Yes	No	No	No	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion
Sulfamethoxazole/Trimethoprim/Isoniazid/Pyridoxine 400/80/150/12.5mg tablet	Yes	N/A	N/A	No	No	No	No	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion

Status
● Yes
● No
● Ineligible for inclusion
● N/A

LTBI: Latent TB Infection
 EML: Essential Medicines List
 EOI: Expression of Interest
 ERP: Expert Review Panel
 SRA: Stringent Regulatory Authority
 WHO PQ: World Health Organization Prequalification of Medicines Programme